Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
Add more filters










Publication year range
1.
Head Neck Pathol ; 14(1): 212-219, 2020 Mar.
Article in English | MEDLINE | ID: mdl-30484069

ABSTRACT

An 11 month old Caucasian male presented with swelling of the right side of the nose and buccal vestibule of unknown duration. Radiographic images revealed a well-circumscribed, hypodense soft tissue mass with a peripheral hyperdense circumference involving the anterior aspect of the right maxilla. The lesion extended from the inferior aspect of the orbital rim superiorly to the maxillary bone inferiorly without invading any nearby structures. The lesion was completely resected via combined extraoral and intraoral approach. The clinical, radiographic, histologic and immunohistochemical features of a sinonasal myxoma in an infant are discussed.


Subject(s)
Maxillary Sinus Neoplasms/pathology , Myxoma/pathology , Humans , Infant , Male
2.
PLoS One ; 14(8): e0221163, 2019.
Article in English | MEDLINE | ID: mdl-31442236

ABSTRACT

Patients with traumatic brain injury (TBI) are frequently diagnosed with depression. Together, these two leading causes of death and disability significantly contribute to the global burden of healthcare costs. However, there are no drug treatments for TBI and antidepressants are considered off-label for depression in patients with TBI. In molecular profiling studies of rat hippocampus after experimental TBI, we found that TBI altered the expression of a subset of small, non-coding, microRNAs (miRNAs). One known neuroprotective compound (17ß-estradiol, E2), and two experimental neuroprotective compounds (JM6 and PMI-006), reversed the effects of TBI on miRNAs. Subsequent in silico analyses revealed that the injury-altered miRNAs were predicted to regulate genes involved in depression. Thus, we hypothesized that drug-induced miRNA profiles can be used to identify compounds with antidepressant properties. To confirm this hypothesis, we examined miRNA expression in hippocampi of injured rats treated with one of three known antidepressants (imipramine, fluoxetine and sertraline). Bioinformatic analyses revealed that TBI, potentially via its effects on multiple regulatory miRNAs, dysregulated transcriptional networks involved in neuroplasticity, neurogenesis, and circadian rhythms- networks known to adversely affect mood, cognition and memory. As did E2, JM6, and PMI-006, all three antidepressants reversed the effects of TBI on multiple injury-altered miRNAs. Furthermore, JM6 reduced TBI-induced inflammation in the hippocampus and depression-like behavior in the forced swim test; these are both properties of classic antidepressant drugs. Our results support the hypothesis that miRNA expression signatures can identify neuroprotective and antidepressant properties of novel compounds and that there is substantial overlap between neuroprotection and antidepressant properties.


Subject(s)
Antidepressive Agents/pharmacology , Brain Injuries, Traumatic/drug therapy , Depression/drug therapy , MicroRNAs/genetics , Animals , Brain Injuries, Traumatic/complications , Brain Injuries, Traumatic/genetics , Brain Injuries, Traumatic/pathology , Computational Biology , Depression/complications , Depression/genetics , Depression/pathology , Disease Models, Animal , Estradiol/pharmacology , Fluoxetine/pharmacology , Gene Expression Regulation/drug effects , Hippocampus/drug effects , Hippocampus/pathology , Humans , Imipramine/pharmacology , Rats , Sertraline/pharmacology , Sulfonamides/pharmacology , Thiazoles/pharmacology
3.
PLoS One ; 14(4): e0214741, 2019.
Article in English | MEDLINE | ID: mdl-30943276

ABSTRACT

There are no existing treatments for the long-term degenerative effects of traumatic brain injury (TBI). This is due, in part, to our limited understanding of chronic TBI and uncertainty about which proposed mechanisms for long-term neurodegeneration are amenable to treatment with existing or novel drugs. Here, we used microarray and pathway analyses to interrogate TBI-induced gene expression in the rat hippocampus and cortex at several acute, subchronic and chronic intervals (24 hours, 2 weeks, 1, 2, 3, 6 and 12 months) after parasagittal fluid percussion injury. We used Ingenuity pathway analysis (IPA) and Gene Ontology enrichment analysis to identify significantly expressed genes and prominent cell signaling pathways that are dysregulated weeks to months after TBI and potentially amenable to therapeutic modulation. We noted long-term, coordinated changes in expression of genes belonging to canonical pathways associated with the innate immune response (i.e., NF-κB signaling, NFAT signaling, Complement System, Acute Phase Response, Toll-like receptor signaling, and Neuroinflammatory signaling). Bioinformatic analysis suggested that dysregulation of these immune mediators-many are key hub genes-would compromise multiple cell signaling pathways essential for homeostatic brain function, particularly those involved in cell survival and neuroplasticity. Importantly, the temporal profile of beneficial and maladaptive immunoregulatory genes in the weeks to months after the initial TBI suggests wider therapeutic windows than previously indicated.


Subject(s)
Brain Injuries, Traumatic/metabolism , Gene Expression Regulation , Acute-Phase Proteins/metabolism , Animals , Brain Injuries, Traumatic/complications , Brain Injuries, Traumatic/immunology , Complement System Proteins/metabolism , Computational Biology , Gene Expression Profiling , Male , NF-kappa B/metabolism , NFATC Transcription Factors/metabolism , Neurodegenerative Diseases/etiology , Neurodegenerative Diseases/metabolism , Principal Component Analysis , Proteostasis , Rats, Sprague-Dawley , Real-Time Polymerase Chain Reaction , Signal Transduction , Toll-Like Receptors/metabolism
4.
Sci Rep ; 8(1): 14994, 2018 Oct 08.
Article in English | MEDLINE | ID: mdl-30297835

ABSTRACT

A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has not been fixed in the paper.

5.
PLoS One ; 12(10): e0185943, 2017.
Article in English | MEDLINE | ID: mdl-29016640

ABSTRACT

Virally mediated RNA interference (RNAi) to knock down injury-induced genes could improve functional outcome after traumatic brain injury (TBI); however, little is known about the consequences of gene knockdown on downstream cell signaling pathways and how RNAi influences neurodegeneration and behavior. Here, we assessed the effects of adeno-associated virus (AAV) siRNA vectors that target two genes with opposing roles in TBI pathogenesis: the allegedly detrimental neuronal nitric oxide synthase (nNOS) and the potentially protective glutathione peroxidase 1 (GPx-1). In rat hippocampal progenitor cells, three siRNAs that target different regions of each gene (nNOS, GPx-1) effectively knocked down gene expression. However, in vivo, in our rat model of fluid percussion brain injury, the consequences of AAV-siRNA were variable. One nNOS siRNA vector significantly reduced the number of degenerating hippocampal neurons and showed a tendency to improve working memory. GPx-1 siRNA treatment did not alter TBI-induced neurodegeneration or working memory deficits. Nevertheless, microarray analysis of laser captured, virus-infected neurons showed that knockdown of nNOS or GPx-1 was specific and had broad effects on downstream genes. Since nNOS knockdown only modestly ameliorated TBI-induced working memory deficits, despite widespread genomic changes, manipulating expression levels of single genes may not be sufficient to alter functional outcome after TBI.


Subject(s)
Brain Injuries, Traumatic/genetics , Dependovirus/genetics , Glutathione Peroxidase/genetics , Memory Disorders/genetics , Nitric Oxide Synthase Type I/genetics , RNA Interference , Animals , Brain Injuries, Traumatic/metabolism , Brain Injuries, Traumatic/physiopathology , Dependovirus/metabolism , Gene Expression Profiling , Gene Knockdown Techniques , Glutathione Peroxidase/antagonists & inhibitors , Glutathione Peroxidase/metabolism , Hippocampus/metabolism , Hippocampus/physiopathology , Laser Capture Microdissection , Male , Maze Learning , Memory Disorders/metabolism , Memory Disorders/physiopathology , Memory, Short-Term/physiology , Metabolic Networks and Pathways/genetics , Microarray Analysis , Neural Stem Cells/cytology , Neural Stem Cells/metabolism , Neurons/metabolism , Neurons/pathology , Nitric Oxide Synthase Type I/antagonists & inhibitors , Nitric Oxide Synthase Type I/metabolism , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Rats , Rats, Sprague-Dawley , Signal Transduction , Glutathione Peroxidase GPX1
6.
Sci Rep ; 7(1): 6645, 2017 07 27.
Article in English | MEDLINE | ID: mdl-28751711

ABSTRACT

The underlying molecular mechanisms of how dysregulated microRNAs (miRNAs) cause neurodegeneration after traumatic brain injury (TBI) remain elusive. Here we analyzed the biological roles of approximately 600 genes - we previously found these dysregulated in dying and surviving rat hippocampal neurons - that are targeted by ten TBI-altered miRNAs. Bioinformatic analysis suggests that neurodegeneration results from a global miRNA-mediated suppression of genes essential for maintaining proteostasis; many are hub genes - involved in RNA processing, cytoskeletal metabolism, intracellular trafficking, cell cycle progression, repair/maintenance, bioenergetics and cell-cell signaling - whose disrupted expression is linked to human disease. Notably, dysregulation of these essential genes would significantly impair synaptic function and functional brain connectivity. In surviving neurons, upregulated miRNA target genes are co-regulated members of prosurvival pathways associated with cellular regeneration, neural plasticity, and development. This study captures the diversity of miRNA-regulated genes that may be essential for cell repair and survival responses after TBI.


Subject(s)
Brain Injuries, Traumatic/physiopathology , Cell Death , Gene Expression Regulation , Hippocampus/physiopathology , Proteostasis Deficiencies/complications , Animals , Brain Injuries, Traumatic/complications , Brain Injuries, Traumatic/genetics , Cell Survival , Gene Expression Profiling , Male , Neurodegenerative Diseases/etiology , Neuronal Plasticity , Neurons/physiology , Proteostasis Deficiencies/etiology , Rats
7.
Rev. colomb. gastroenterol ; 32(1): 7-19, 2017. ilus
Article in Spanish | LILACS | ID: biblio-900668

ABSTRACT

Introducción: el cáncer gástrico es muy frecuente en Colombia y es la primera causa de muerte por cáncer. De acuerdo con la cascada de Correa existen unas etapas progresivas en la formación de esta enfermedad, que van de la gastritis, pasando por la atrofia, metaplasia y displasia, hasta el cáncer. En esas etapas intermedias se pudiera detectar y prevenir, pero no existen marcadores en sangre diferentes al pepsinógeno que puedan ayudar a detectar las etapas premalignas ni a diagnosticar el cáncer. Por lo cual, las investigaciones que ayuden a descubrir nuevos biomarcadores son de gran importancia. Objetivos: el objetivo de este trabajo es identificar marcadores moleculares (perfil de expresión de ARNm) que distingan a los pacientes con condiciones premalignas (atrofia, metaplasia) y cáncer gástrico, de aquellos pacientes que solo tienen gastritis. Metodología: se tomaron pacientes en cada una de las etapas de la cascada de Correa, los cuales proporcionaron una muestra, previo consentimiento firmado, de 2,5 mL de sangre en ayunas para el análisis de expresión de genes tomadas después de la endoscopia inicial. La sangre se colocó en un tubo de ARN sanguíneo PAXgene; luego, el ARN se extrajo de la sangre y se analizó usando una plataforma de microarrays, los cuales identificaron cambios de expresión de ARN mensajero que permitieron diferenciar cada una de las etapas descritas. Resultados: se incluyeron 89 pacientes, y en los hallazgos endoscópicos se encontró gastritis crónica antral en 27 pacientes (30,3%), cáncer gástrico avanzado en 25 (28%), pangastritis crónica en 15 (16,8%), cáncer temprano en 7 (7,8%), sospecha de metaplasia intestinal en 6 (6,7%), sospecha de gastritis atrófica en 3 (3,3%) y úlcera péptica en 2 casos (2,2%). Cuando se revisó el informe patológico se halló gastritis crónica en 34 pacientes (22 mujeres), adenocarcinoma intestinal en 20 (4 mujeres), metaplasia intestinal 18 casos (13 mujeres), cáncer tipo difuso en 11 (7 mujeres), displasia de bajo grado en 4 y de alto grado en 1, y atrofia sola en 1 paciente. En el análisis de expresión genética se encontraron 48 genes que permitieron determinar a los pacientes con gastritis crónica de aquellos con cáncer gástrico. También se hallaron 14 genes para diferenciar los pacientes con cáncer difuso de los de tipo intestinal, y un grupo de 48 genes que ayudó a distinguir los pacientes con gastritis crónica de los de metaplasia intestinal. Conclusiones: este es el primer trabajo en Colombia, y a nivel mundial, que permite identificar nuevos biomarcadores a través de la expresión genética del ARN mensajero, el cual diferencia en sangre las etapas de la cascada de Correa, y permite diagnosticar el cáncer gástrico. Es probable que en un futuro se puedan utilizar como una prueba diagnóstica o de seguimiento.


Introduction: Gastric cancer is very common in Colombia where it is the leading cause of death due to cancer. According to the Pelayo Corre, there is a cascade of stages from gastritis through atrophy, metaplasia and dysplasia to cancer. In the intermediate stages, it might be possible to detect and prevent the development of cancer, but there are no known markers in the blood other than pepsinogen to help to detect premalignant stages and diagnose cancer. Research is the key to discovery of new biomarkers. Objective: The aim of this work is to identify molecular markers (mRNA expression profiles) that distinguish patients who have premalignant conditions (atrophy, metaplasia) and gastric cancer from patients who only have gastritis. Methodology: Following an initial endoscopy, patients in each stage of the Pelayo cascade fasted and then provided a 2.5 ml blood sample which was analyzed for gene expression. All participating patients signed consent forms prior to tests. The blood was placed in a PAXgene RNA Blood tube, RNA was extracted from the blood and then analyzed. A microarray platform which identified changes in messenger RNA expression was used to differentiate each of the stages described. Results: Endoscopic findings for the eighty-nine patients included showed that 25 (28%) had advanced gastric cancer, 7 (7.8%) had early cancer, 27 (30.3%) had chronic antral gastritis, 15 (16.8%) had chronic pangastritis, three (3.3%) were suspected of having atrophic gastritis, six (6.6%) were suspected of having intestinal metaplasia, and two (2.2%) had peptic ulcers. Pathological reports showed 20 cases of intestinal adenocarcinoma (4 women), 11 cases diffuse cancer (7 women), 34 cases of chronic gastritis (22 women), one case of atrophy alone, 18 cases of intestinal metaplasia (13 women), four cases of low-grade dysplasia, and one case of high-grade dysplasia. The analysis of genetic expression found 48 genes which could be used for differentiation of patients with chronic gastritis from patients with gastric cancer. We also found 14 genes that could be used to differentiate patients with diffuse cancer from patients with intestinal type gastric cancer, and a group of 48 genes that could be used to differentiate patients with chronic gastritis from those with intestinal metaplasia. Conclusions: This is the first work anywhere in the world that has identified new biomarkers through the genetic expression of messenger RNA which differentiates the stages of the Pelayo Correa cascade and permits diagnosis of gastric cancer. It is likely that in the future they may be used as diagnostic and/or follow-up tests.


Subject(s)
Biomarkers , Stomach Neoplasms/prevention & control , Atrophy , Metaplasia
8.
Clin Adv Periodontics ; 6(2): 64-69, 2016 May.
Article in English | MEDLINE | ID: mdl-31535492

ABSTRACT

INTRODUCTION: A peripheral ossifying fibroma (POF) presents similarly to other soft tissue reactive lesions, such as pyogenic granuloma or peripheral giant cell granuloma, and yet the pathogenesis of POFs remains undetermined. Surgical excision is the standard of care for a POF, but given their propensity to present in the esthetic area and likelihood for recurrence, these lesions must be addressed with careful technique to prevent mucogingival defects. To the best of the authors' knowledge, this is the first report to show that complete excision of a recurrent POF followed by a pouch recipient bed preparation for simultaneous soft tissue augmentation, and this technique may prove to be a novel and predictable approach to successfully treat such cases. CASE PRESENTATION: A 57-year-old female presented with a firm, sessile, painless, broad-based, gingival mass between the maxillary central and lateral incisors. It was excised conservatively and allowed to heal by secondary intention. A histopathologic diagnosis of POF was made, but after 12 months, the mass recurred. Subsequent excision of the recurrent lesion was performed by removing the free gingival margin and surrounding tissues. All gingival and periosteal tissues involved were removed aggressively in addition to thorough root planing. Peripheral undermining of the marginal tissue was performed to create a pouch, preparing a recipient site for simultaneous soft tissue augmentation. Palatal connective tissue was harvested and sutured into the recipient site such that the tissue defect was filled, and the exposed root remained completely covered after 48 months. CONCLUSION: Aggressive surgical excision with simultaneous soft tissue augmentation may successfully resolve the pathologic process and ensure esthetic success in cases of recurrent POFs.

9.
PLoS One ; 10(12): e0144345, 2015.
Article in English | MEDLINE | ID: mdl-26640957

ABSTRACT

BACKGROUND: Animal models that mimic human biology are important for successful translation of basic science discoveries into the clinical practice. Recent studies in rodents have demonstrated the efficacy of TLR4 agonists as immunomodulators in models of infection. However, rodent models have been criticized for not mimicking important characteristics of the human immune response to microbial products. The goal of this study was to compare genomic responses of human and sheep blood to the TLR4 agonists lipopolysaccharide (LPS) and monophosphoryl lipid A (MPLA). METHODS: Venous blood, withdrawn from six healthy human adult volunteers (~ 28 years old) and six healthy adult female sheep (~3 years old), was mixed with 30 µL of PBS, LPS (1µg/mL) or MPLA (10µg/mL) and incubated at room temperature for 90 minutes on a rolling rocker. After incubation, 2.5 mL of blood was transferred to Paxgene Blood RNA tubes. Gene expression analysis was performed using an Agilent Bioanalyzer with the RNA6000 Nano Lab Chip. Agilent gene expression microarrays were scanned with a G2565 Microarray Scanner. Differentially expressed genes were identified. RESULTS: 11,431 human and 4,992 sheep probes were detected above background. Among them 1,029 human and 175 sheep genes were differentially expressed at a stringency of 1.5-fold change (p<0.05). Of the 175 sheep genes, 54 had a known human orthologue. Among those genes, 22 had > 1.5-fold changes in human samples. Genes of major inflammatory mediators, such as IL-1, IL-6 and IL-8, TNF alpha, NF-kappaB, ETS2, PTGS2, PTX3, CXCL16, KYNU, and CLEC4E were similarly (>2-fold) upregulated by LPS and MPLA in both species. CONCLUSION: The genomic responses of peripheral blood to LPS and MPLA in sheep are quite similar to those observed in humans, supporting the use of the ovine model for translational studies that mimic human inflammatory diseases and the study of TLR-based immunomodulators.


Subject(s)
Blood/drug effects , Gene Expression Regulation/drug effects , Lipid A/analogs & derivatives , Lipopolysaccharides/pharmacology , Toll-Like Receptor 4/agonists , Adult , Animals , Blood/immunology , Female , Fluorescence , High-Throughput Nucleotide Sequencing/methods , Humans , Lipid A/pharmacology , Sheep , Species Specificity
10.
PLoS One ; 10(1): e0116285, 2015.
Article in English | MEDLINE | ID: mdl-25635769

ABSTRACT

Oral squamous cell carcinomas (OSCC) induced in F344 rats by 4-nitroquinoline-1-oxide (4-NQO) demonstrate considerable phenotypic similarity to human oral cancers. Gene expression studies (microarray and PCR) were coupled with methylation analysis of selected genes to identify molecular markers of carcinogenesis in this model and potential biochemical and molecular targets for oral cancer chemoprevention. Microarray analysis of 11 pairs of OSCC and site-matched phenotypically normal oral tissues from 4-NQO-treated rats identified more than 3500 differentially expressed genes; 1735 genes were up-regulated in rat OSCC versus non-malignant tissues, while 1803 genes were down-regulated. In addition to several genes involved in normal digestion, genes demonstrating the largest fold increases in expression in 4-NQO-induced OSCC include three lipocalins (VEGP1, VEGP2, LCN2) and three chemokines (CCL, CXCL2, CXCL3); both classes are potentially druggable targets for oral cancer chemoprevention and/or therapy. Down-regulated genes in 4-NQO-induced OSCC include numerous keratins and keratin-associated proteins, suggesting that alterations in keratin expression profiles may provide a useful biomarker of oral cancer in F344 rats treated with 4-NQO. Confirming and extending our previous results, PTGS2 (cyclooxygenase-2) and several cyclooxygenase-related genes were significantly up-regulated in 4-NQO-induced oral cancers; up-regulation of PTGS2 was associated with promoter hypomethylation. Rat OSCC also demonstrated increased methylation of the first exon of APC2; the increased methylation was correlated with down-regulation of this tumor suppressor gene. Overexpression of pro-inflammatory chemokines, hypomethylation of PTGS2, and hypermethylation of APC2 may be causally linked to the etiology of oral cancer in this model.


Subject(s)
Carcinoma, Squamous Cell/metabolism , Chemokines/metabolism , Cyclooxygenase 2/genetics , Genes, Tumor Suppressor , Lipocalins/metabolism , Mouth Neoplasms/metabolism , 4-Nitroquinoline-1-oxide , Animals , Carcinoma, Squamous Cell/chemically induced , Carcinoma, Squamous Cell/genetics , Chemokines/genetics , Cyclooxygenase 1/genetics , Cyclooxygenase 1/metabolism , Cyclooxygenase 2/metabolism , DNA Methylation , Gene Expression Regulation, Neoplastic , Keratins/genetics , Keratins/metabolism , Lipocalins/genetics , Male , Membrane Proteins/genetics , Membrane Proteins/metabolism , Mouth Neoplasms/chemically induced , Mouth Neoplasms/genetics , Oligonucleotide Array Sequence Analysis , Promoter Regions, Genetic , Rats, Inbred F344 , Tongue/pathology , Transcriptome
11.
PLoS One ; 9(11): e113175, 2014.
Article in English | MEDLINE | ID: mdl-25405629

ABSTRACT

The present experiments were performed to determine the roles of estrogen receptors α and ß (ERα and ERß) in normal and neoplastic development in the mouse mammary gland. In wild-type mice, in vivo administration of estradiol (E) + progesterone (P) stimulated mammary ductal growth and alveolar differentiation. Mammary glands from mice in which the ERß gene has been deleted (ßERKO mice) demonstrated normal ductal growth and differentiation in response to E + P. By contrast, mammary glands from mice in which the ERα gene has been deleted (αERKO mice) demonstrated only rudimentary ductal structures that did not differentiate in response to E + P. EGF demonstrates estrogen-like activity in the mammary glands of αERKO mice: treatment of αERKO mice with EGF + P (without E) supported normal mammary gland development, induced expression of progesterone receptor (PR), and increased levels of G-protein-coupled receptor (GPR30) protein. Mammary gland development in ßERKO mice treated with EGF + P was comparable to that of wild-type mice receiving EGF + P; EGF had no statistically significant effects on the induction of PR or expression of GPR30 in mammary glands harvested from either wild-type mice or ßERKO mice. In vitro exposure of mammary glands to 7,12-dimethylbenz[a]anthracene (DMBA) induced preneoplastic mammary alveolar lesions (MAL) in glands from wild-type mice and ßERKO mice, but failed to induce MAL in mammary glands from αERKO mice. Microarray analysis of DMBA-treated mammary glands identified 28 functional pathways whose expression was significantly different in αERKO mice versus both ßERKO and wild-type mice; key functions that were differentially expressed in αERKO mice included cell division, cell proliferation, and apoptosis. The data demonstrate distinct roles for ERα and ERß in normal and neoplastic development in the mouse mammary gland, and suggest that EGF can mimic the ERα-mediated effects of E in this organ.


Subject(s)
Breast Neoplasms/metabolism , Estrogen Receptor alpha/metabolism , Estrogen Receptor beta/metabolism , Mammary Glands, Human/drug effects , 9,10-Dimethyl-1,2-benzanthracene/toxicity , Animals , DNA Primers/genetics , Estradiol/administration & dosage , Estrogen Receptor alpha/genetics , Estrogen Receptor beta/genetics , Female , Humans , Immunohistochemistry , Mammary Glands, Human/growth & development , Mammary Glands, Human/metabolism , Mice , Mice, Knockout , Microarray Analysis , Progesterone/administration & dosage , Real-Time Polymerase Chain Reaction , Receptors, Estrogen/metabolism , Receptors, G-Protein-Coupled/metabolism
12.
Urology ; 81(6): 1303-7, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23622774

ABSTRACT

OBJECTIVE: To assess the use of circulating tumor cells (CTCs) as a longitudinal endpoint factor for clinical monitoring of patients with prostate cancer and to evaluate the association among the baseline CTC number, various clinical characteristics, and survival. MATERIALS AND METHODS: The CTCs were enumerated using the CellSearch Food and Drug Administration-cleared CTC kit in 202 patients with prostate cancer. Variables, including metastatic site, prostate-specific antigen level, Gleason score, testosterone level, and use of androgen treatment, were tested for association with the CTC number. The probability of patient survival over time was estimated using the Kaplan-Meier method. RESULTS: The baseline CTC numbers were strongly associated with survival (P <.0001), with overall survival significantly poorer in patients with ≥5 CTCs. Significantly greater CTC numbers were observed in patients with bone metastasis (mean 41.12 CTCs) than in those with lymph node metastasis (mean 2.53 CTC, P = .026). Analysis of the association between the CTC count and prostate-specific antigen level revealed a weak positive correlation (correlation coefficient r = 0.2695, P = .0007). The CTC number also correlated with the Gleason score (P = .0138) and lower testosterone level (P <.0001). Patients without androgen depletion had significantly lower CTC numbers (mean 2.70) than those with androgen depletion (mean 26.39, P <.0001). CONCLUSION: The baseline CTC counts were predictive of patient survival and correlated significantly with the clinical characteristics of patients with prostate cancer. Our study results have confirmed previous findings that support the use of CTC enumeration as a prognostic biomarker for patients with prostate cancer.


Subject(s)
Antigens, Neoplasm/metabolism , Biomarkers, Tumor/blood , Cell Adhesion Molecules/metabolism , Neoplastic Cells, Circulating/metabolism , Prostatic Neoplasms/blood , Prostatic Neoplasms/pathology , Aged , Aged, 80 and over , Bone Neoplasms/blood , Bone Neoplasms/secondary , Epithelial Cell Adhesion Molecule , Humans , Kaplan-Meier Estimate , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Grading , Proportional Hazards Models , Prostate-Specific Antigen/blood , Retrospective Studies , Testosterone/blood
13.
Biol Reprod ; 84(3): 487-94, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21076082

ABSTRACT

In invertebrates and amphibians, informational macromolecules in egg cytoplasm are organized to provide direction to the formation of embryonic lineages, but it is unclear whether vestiges of such prepatterning exist in mammals. Here we examined whether twin blastomeres from 2-cell stage mouse embryos differ in mRNA content. mRNA from 26 blastomeres derived from 13 embryos approximately mid-way through their second cell cycle was subjected to amplification. Twenty amplified samples were hybridized to arrays. Of those samples that hybridized successfully, 12 samples in six pairs were used in the final analysis. Probes displaying normalized values >0.25 (n = 4573) were examined for consistent bias in expression within blastomere pairs. Although transcript content varied between both individual embryos and twin blastomeres, no consistent asymmetries were observed for the majority of genes, with only 178 genes displaying a >1.4-fold difference in expression across all six pairs. Although class discovery clustering showed that blastomere pairs separated into two distinct groups in terms of their differentially expressed genes, when the data were tested for significance of asymmetrical expression, only 39 genes with >1.4-fold change ratios in six of six blastomere pairs passed the two-sample t-test (P < 0.05). Transcripts encoding proteins implicated in RNA processing and cytoskeletal organization were among the most abundant, differentially distributed mRNA, suggesting that a stochastically based lack of synchrony in cell cycle progression between the two cells might explain at least some and possibly all of the asymmetries in transcript composition.


Subject(s)
Blastomeres/cytology , Blastomeres/metabolism , Cleavage Stage, Ovum/cytology , Twinning, Monozygotic , Animals , Blastomeres/chemistry , Cells, Cultured , Cleavage Stage, Ovum/metabolism , Embryo, Mammalian , Female , Gene Expression Profiling , Gene Expression Regulation, Developmental , Male , Mice , Microarray Analysis , Pregnancy , RNA, Messenger/analysis , RNA, Messenger/isolation & purification , Twinning, Monozygotic/genetics , Twinning, Monozygotic/physiology , Twins
14.
J Cell Biochem ; 110(6): 1324-33, 2010 Aug 15.
Article in English | MEDLINE | ID: mdl-20564226

ABSTRACT

25-Hydroxyvitamin D(3) (25(OH)D(3)) is a prohormone and a major vitamin D metabolite. The discovery of (25(OH)D(3)) 1 alpha-hydroxylase in many vitamin D target organs has yielded an increased interest in defining the role(s) of 25(OH)D(3) in these tissues. The etiology of cancer appears to be complex and multi-factorial. Cellular stress (e.g., DNA damage, hypoxia, oncogene activation) has been identified as one of the key factors responsible for initiating the carcinogenesis process. In this study, we investigated whether 25(OH)D(3) protects breast epithelial cells from cellular stress using an established breast epithelial cell line MCF12F. To better elucidate the role of 25(OH)D(3) in the stress response, we used multiple in vitro stress models including serum starvation, hypoxia, oxidative stress, and apoptosis induction. Under all these stress conditions, 25(OH)D(3) (250 nmol/L) treatment significantly protected cells against cell death. Low-serum stress induced p53 expression accompanied with downregulation of PCNA, the presence of 25(OH)D(3) consistently inhibited the alteration of p53 and PCNA, suggesting that these molecules were involved in the stress process and may be potential target genes of 25(OH)D(3). miRNA microarray analysis demonstrated that stress induced by serum starvation caused significant alteration in the expression of multiple miRNAs including miR182, but the presence of 25(OH)D(3) effectively reversed this alteration. These data suggest that there is a significant protective role for 25(OH)D(3) against cellular stress in the breast epithelial cells and these effects may be mediated by altered miRNA expression.


Subject(s)
Apoptosis/drug effects , Calcifediol/pharmacology , Epithelial Cells/drug effects , Oxidative Stress/drug effects , Blotting, Western , Breast/cytology , Breast/metabolism , Cell Hypoxia , Cell Line , Cell Line, Tumor , Culture Media/chemistry , Culture Media/pharmacology , Culture Media, Serum-Free/pharmacology , Cysteine Proteinase Inhibitors/pharmacology , Dose-Response Relationship, Drug , Epithelial Cells/cytology , Epithelial Cells/metabolism , Female , Humans , Hydrogen Peroxide/pharmacology , Leupeptins/pharmacology , MicroRNAs/genetics , MicroRNAs/metabolism , Oligonucleotide Array Sequence Analysis , Oxidants/pharmacology , Proliferating Cell Nuclear Antigen/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Tumor Suppressor Protein p53/metabolism , Vitamins/pharmacology
15.
Proc Natl Acad Sci U S A ; 107(12): 5557-62, 2010 Mar 23.
Article in English | MEDLINE | ID: mdl-20212133

ABSTRACT

Diet during pregnancy influences the future health of a woman's offspring, with outcomes differing depending on the child's sex. Because the placenta buffers the fetus from the mother, we examined the impact of diet and fetal sex on placental gene expression in mice fed either a very-high-fat, low-fat, chow diet of intermediate caloric density. At day 12.5 of pregnancy, placental RNA was extracted and analyzed by microarray. The expression of 1,972 genes was changed more than 2-fold (P < 0.05) in comparisons across diet in at least one of the three groups. Female placentae demonstrated more striking alterations in gene expression in response to maternal diet than male placentae. Notably, each diet provided a distinctive signature of sexually dimorphic genes, with expression generally higher in genes (651 out of 700) from female placentae than those from male placentae. Several genes normally considered as characteristic of kidney function were affected by diet, including genes regulating ion balance and chemoreception. The placenta also expressed most of the known olfactory receptor genes (Olfr), which may allow the placenta to sense odorant molecules and other minor dietary components, with transcript levels of many of these genes influenced by diet and fetal sex. In conclusion, gene expression in the murine placenta is adaptive and shaped by maternal diet. It also exhibits pronounced sexual dimorphism, with placentae of females more sensitive to nutritional perturbations than placentae of males.


Subject(s)
Diet , Gene Expression , Placenta/metabolism , Sex Characteristics , Animals , Dietary Fats/administration & dosage , Female , Gene Expression Profiling , Male , Maternal-Fetal Exchange/genetics , Mice , Oligonucleotide Array Sequence Analysis , Placental Hormones/genetics , Pregnancy
16.
Cancer Prev Res (Phila) ; 2(11): 942-50, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19861542

ABSTRACT

An emphasis in early detection and more effective treatments has decreased the mortality rate of breast cancer. Despite this decrease, breast cancer continues to be the leading cause of death among women between 40 and 55 years of age and is the second overall cause of death among women. Hence, the aim of the present study was to assess the therapeutic efficacy of deguelin, a rotenoid isolated from several plant species, which has been reported to have chemopreventive and/or chemotherapeutic effects in skin, mammary, colon, and lung cancers. The effect of deguelin on cell proliferation was evaluated using four human breast carcinoma cell lines (MCF-7, BT474, T47D, and MDA-MB-231) by cell count and MTT. Moreover, apoptosis was evaluated by acridine/ethidium staining and DNA laddering. Gene expression changes following deguelin treatment in MDA-MB-231 cells was assessed through microarray analysis. Deguelin at 1 mumol/L was found to inhibit the growth of the breast cancer cell lines tested with a range of 37% to 87%. The highest inhibition was noted for the MDA-MB-231 cell line (MDA-MB-231>BT474>MCF7>T47D>MCF12F). An arrest at the S phase of the cell cycle and apoptosis were shown in the MDA-MB-231 cells treated with deguelin. The microarray profile indicated differential expression of two independent pathways, including clusters of apoptosis and Wnt/beta-catenin signaling genes in cells as a result of deguelin treatment. These studies support the antiproliferative effects of deguelin in human breast cancer cells and, perhaps more importantly, illustrate novel actions by deguelin in the Wnt signaling pathway.


Subject(s)
Breast Neoplasms/pathology , Cell Proliferation/drug effects , Rotenone/analogs & derivatives , Signal Transduction/drug effects , Wnt Proteins/metabolism , Apoptosis/drug effects , Biomarkers, Tumor/metabolism , Blotting, Western , Breast Neoplasms/metabolism , Cell Cycle/drug effects , Female , Gene Expression Profiling , Humans , Oligonucleotide Array Sequence Analysis , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Rotenone/pharmacology , Tumor Cells, Cultured , Wnt Proteins/genetics
17.
Toxicol Sci ; 99(2): 612-27, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17630414

ABSTRACT

Tamoxifen (TAM) is a nonsteroidal antiestrogen that prevents estrogen receptor-positive breast cancer in rodents and humans. Bexarotene (BEX), a selective agonist for retinoid X receptors, inhibits mammary carcinogenesis in rodents. The present study was conducted to support the preclinical development of TAM (tamoxifen citrate) + BEX for use in breast cancer chemoprevention, and to investigate the influence of these agents on hepatic gene expression. Female CD rats (20 per group) received daily oral (gavage) exposure to TAM (0 or 60 microg/kg/day) and/or BEX (0, 5, 15, or 45 mg/kg/day) for a minimum of 90 days. BEX induced mild, dose-related anemia and dose-related increases in serum alkaline phosphatase, cholesterol, triglycerides, and calcium levels, and increased platelet counts. TAM had no biologically significant effect on any clinical pathology parameter and did not alter the effects of BEX on these endpoints. Microscopic alterations induced by BEX included epidermal hyperplasia, hyperkeratosis (stomach), and cytoplasmic clearing (liver). Microscopic changes in TAM-treated rats were limited to mucous cell hypertrophy in the cervix and vagina. The toxicity of administration of the combination of TAM + BEX can generally be predicted on the basis of the toxicity of each drug as a single agent. BEX induced dose-related alterations in the expression of several genes involved in steroid, drug, and/or fatty acid metabolism; TAM did not alter these effects of BEX. Differential expression of genes involved in drug and lipid metabolism may underlie the observed effects of BEX on cholesterol and triglyceride levels and its effects on liver histology.


Subject(s)
Tamoxifen/toxicity , Tetrahydronaphthalenes/toxicity , Animals , Bexarotene , Dimerization , Dose-Response Relationship, Drug , Female , Gene Expression Profiling , Liver/drug effects , Liver/metabolism , Oligonucleotide Array Sequence Analysis , PPAR alpha/chemistry , Rats , Rats, Sprague-Dawley , Receptors, Retinoic Acid/agonists , Retinoid X Receptors/chemistry , Reverse Transcriptase Polymerase Chain Reaction , Tamoxifen/blood , Tetrahydronaphthalenes/blood , Toxicogenetics
SELECTION OF CITATIONS
SEARCH DETAIL
...